[PDF] Recombinant Antibodies For Infectious Diseases eBook
Recombinant Antibodies For Infectious Diseases Book in PDF, ePub and Kindle version is available to download in english. Read online anytime anywhere directly from your device. Click on the download button below to get a free pdf file of Recombinant Antibodies For Infectious Diseases book. This book definitely worth reading, it is an incredibly well-written.
There are many principles and applications of recombinant antibodies for infectious diseases. The preferred technology associated to recombinant antibody generation is mainly phage display. The adaptation of antibodies for infectious diseases is an area lacking information as most literature is focused on oncology or autoimmunity. This project highlights the power and potential of antibody phage display for infectious diseases. In addition to that, supplementary information regarding technologies associated to antibody generation and engineering in the context of infectious disease will also help to provide greater insight to the potential of recombinant antibodies for infectious diseases.
Author : James E. Crowe, Jr. Publisher : John Wiley & Sons Page : 601 pages File Size : 14,64 MB Release : 2015-05-01 Category : Medical ISBN : 1683673409
State-of-the-art reviews covering major aspects of antibodies and intervention against infectious diseases The connection between antibodies and infectious diseases has spawned entire related fields of study. Antibodies for Infectious Diseases presents perspectives from leading research scientists and summarizes the amazing progress in this area into a single definitive source. Providing a broad survey of the most important aspects of the field of antibodies for infectious diseases, this book presents general features pertaining to structure, function, isotype, and the role of complement in antibody function examines the role of antibodies in antimicrobial immunity with specific targets details new methods for expression of monoclonal antibodies, in plants or by transfer of antibody genes for in vivo expression in treated subjects Antibodies for Infectious Diseases is a comprehensive reference for researchers, pharmaceutical developers, and health care professionals on the status of the development of antibody-based therapies for treating infectious diseases. It is also useful as supplemental reading for upper level life sciences students. If you are looking for online access to the latest clinical microbiology content, please visit www.wiley.com/learn/clinmicronow.
Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.
As new recombinant DNA technology continues to join with cellular and molecular immunology, the field of antibody engineering has become a flourishing discipline. Antibody genes are now being cloned, genetically manipulated, and expressed to produce antigen binding proteins. Recombinant Antibodies addresses this burgeoning field with its comprehensive survey of the developing possibilities for producing specific antibodies by combinatorial methods. Following a comprehensive introduction to the field, the book is divided into four parts: a detailed introduction to the underlying concepts of recombinant antibodies, a description of the various methods for the generation of recombinant antibodies, their production and purification, and various designs and applications of genetically engineered proteins. The combination of these techniques substantially extends the functionality of natural antibodies. In addition, the book will focus on: Hybridoma immortalization. Generation and functional screening of highly complex antibody gene libraries. Human monoclonal antibodies to highly toxic and pathogenic antigens. Improving specificity or affinity of antibodies. New agents for cancer diagnosis and therapy. Genetic fusions for the production of bi- and multifunctional molecules. Production of large quantities of recombinant antibodies. New methods of purification. Emerging technologies. Recombinant Antibodies is the first general overview of the emerging field of antibody engineering and will serve as the definitive source for researchers and engineers in biology and medicine, biochemistry, immunology, and molecular biology, as well as anyone who is interested in biotechnology and antibody engineering.
The immune system is a network of cells, tissues, and organs that work together to defend the body against attacks by "foreign" invaders. Invaders are primarily microbes such as bacteria, viruses, parasites and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system's job to keep them out or, failing that, to seek out and destroy them. When the immune system hits the wrong target or is crippled, however, it can unleash seversl diseases, including allergy, arthritis or immune disorders.
More than ever, antibodies are being recognized as a major drug modality in a variety of diseases, including cancer, autoimmune diseases, infectious diseases, or even neurodegenerative disorders. Over 30 therapeutic antibodies have been approved and novel molecules are entering clinical trials at an average rate of 50 per year and that is predicted to continue well into the future. Notwithstanding the many achievements already made in the field, there is still a lot of room for improvements for these molecules in terms of activity, and a plethora of approaches have been attempted to optimize these molecules. Antibody Engineering: Methods and Protocols, Second Edition was compiled to give complete and easy access to a variety of antibody engineering techniques, starting from the creation of antibody repertoires and efficient ways to select binders from these repertoires, to their production in various hosts, their detailed characterization using various well established techniques, and to the modification and optimization of these lead molecules in terms of binding activity, specificity, size, shape, and more. Written in the successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, Antibody Engineering: Methods and Protocols, Second Edition serves as an invaluable resource for both experts and those new to the field, and most of all as a source of inspiration for the creation of the antibodies of tomorrow.
Author : National Research Council Publisher : National Academies Press Page : 74 pages File Size : 41,77 MB Release : 1999-05-06 Category : Medical ISBN : 0309173051
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
Immune-based therapies are being studied extensively in a variety of immunological conditions due to their high precision and sensitivity. Monoclonal antibody (mAb) technology is a major advancement in the treatment of several infectious diseases, malignancies, and immunological disorders. This book provides comprehensive information about technologies, characterization, and application of mAbs in the clinic and laboratory.
Author : National Research Council Publisher : National Academies Press Page : 102 pages File Size : 47,75 MB Release : 2006-01-03 Category : Medical ISBN : 0309180686
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.